| 4.57 0.03 (0.66%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.89 |
1-year : | 6.36 |
| Resists | First : | 5.04 |
Second : | 5.44 |
| Pivot price | 4.57 |
|||
| Supports | First : | 4.4 | Second : | 3.66 |
| MAs | MA(5) : | 4.61 |
MA(20) : | 4.64 |
| MA(100) : | 5.51 |
MA(250) : | 5.15  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 38.9 |
D(3) : | 42.6 |
| RSI | RSI(14): 39.8 |
|||
| 52-week | High : | 6.71 | Low : | 3.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OABI ] has closed above bottom band by 47.4%. Bollinger Bands are 65.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.63 - 4.66 | 4.66 - 4.68 |
| Low: | 4.45 - 4.47 | 4.47 - 4.49 |
| Close: | 4.53 - 4.57 | 4.57 - 4.61 |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Fri, 10 May 2024
Zurcher Kantonalbank Zurich Cantonalbank Grows Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Thu, 09 May 2024
OmniAb, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:OABI) - Seeking Alpha
Wed, 08 May 2024
Federated Hermes Inc. Purchases New Shares in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Tue, 07 May 2024
OmniAb (OABI) Set to Announce Earnings on Thursday - Defense World
Mon, 22 Apr 2024
OmniAb to Report First Quarter 2024 Financial Results on May 9 - Quantisnow
Tue, 02 Apr 2024
OABI Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 118 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 74.2 (%) |
| Shares Short | 5,510 (K) |
| Shares Short P.Month | 5,080 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | -148.2 % |
| Operating Margin | -430.2 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | -86.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 24 (M) |
| PE Ratio | -8.97 |
| PEG Ratio | 0 |
| Price to Book value | 1.69 |
| Price to Sales | 15.73 |
| Price to Cash Flow | 228.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|